GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.20% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2017-02-27
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was 0.20%, a 100.00% increase from fiscal 2015.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2015 was 0.10%, a 50.00% decline from fiscal 2014.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2014 was 0.20%, a 66.67% decline from fiscal 2013.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2013 was 0.60%, a 100.00% increase from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2016-12-31 | 0.20% 10-K · filed 2017-02-27 |
| 2015-12-31 | 0.10% 10-K · filed 2017-02-27 |
| 2014-12-31 | 0.20% 10-K · filed 2017-02-27 |
| 2013-12-31 | 0.60% 10-K · filed 2016-02-24 |
| 2012-12-31 | 0.30% 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |